Relapsing Multiple Sclerosis: FDA Approves Two New Drugs

Earlier this year, the FDA granted approval of Mayzent (siponimod) to Novartis for relapsing multiple sclerosis (MS). As of November 2019, Novartis has received positive feedback. Individuals take Mayzent in tablet form once a day; it is the first treatment…